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Abstract
Background:  The hedgehog pathway plays a critical role in the development of prostate.
However, the role of the hedgehog pathway in prostate cancer is not clear. Prostate cancer is the
second most prevalent cause of cancer death in American men. Therefore, identification of novel
therapeutic targets for prostate cancer has significant clinical implications.
Results: Here we report that activation of the hedgehog pathway occurs frequently in advanced
human prostate cancer. We find that high levels of hedgehog target genes, PTCH1 and hedgehog-
interacting protein (HIP), are detected in over 70% of prostate tumors with Gleason scores 8–10,
but in only 22% of tumors with Gleason scores 3–6. Furthermore, four available metastatic tumors
all have high expression of PTCH1 and HIP. To identify the mechanism of the hedgehog signaling
activation, we examine expression of Su(Fu) protein, a negative regulator of the hedgehog pathway.
We find that Su(Fu) protein is undetectable in 11 of 27 PTCH1 positive tumors, two of them
contain somatic loss-of-function mutations of Su(Fu). Furthermore, expression of sonic hedgehog
protein is detected in majority of PTCH1 positive tumors (24 out of 27). High levels of hedgehog
target genes are also detected in four prostate cancer cell lines (TSU, DU145, LN-Cap and PC3).
We demonstrate that inhibition of hedgehog signaling by smoothened antagonist, cyclopamine,
suppresses hedgehog signaling, down-regulates cell invasiveness and induces apoptosis. In addition,
cancer cells expressing Gli1 under the CMV promoter are resistant to cyclopamine-mediated
apoptosis. All these data suggest a significant role of the hedgehog pathway for cellular functions of
prostate cancer cells.
Conclusion: Our data indicate that activation of the hedgehog pathway, through loss of Su(Fu) or
overexpression of sonic hedgehog, may involve tumor progression and metastases of prostate
cancer. Thus, targeted inhibition of hedgehog signaling may have significant implications of prostate
cancer therapeutics.
Published: 13 October 2004
Molecular Cancer 2004, 3:29 doi:10.1186/1476-4598-3-29
Received: 22 September 2004
Accepted: 13 October 2004
This article is available from: http://www.molecular-cancer.com/content/3/1/29
© 2004 Sheng et al; licensee BioMed Central Ltd. 
This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Molecular Cancer 2004, 3:29 http://www.molecular-cancer.com/content/3/1/29
Page 2 of 13
(page number not for citation purposes)
Background
The hedgehog (Hh) pathway plays a critical role in embry-
onic development and tissue polarity [1]. Secreted Hh
molecules bind to the receptor patched  (PTC-PTCH1,
PTCH2), thereby alleviating PTC-mediated suppression of
smoothened (SMO), a putative seven-transmembrane pro-
tein. SMO signaling triggers a cascade of intracellular
events, leading to activation of the pathway through GLI-
dependent transcription [2]. The hedgehog receptor
PTCH1 is also a target gene of this pathway, which forms
a negative feedback mechanism to maintain the pathway
activity at an appropriate level in a given cell. Activation of
Hh signaling through loss-of-function somatic mutations
of PTCH1 in human basal cell carcinomas (BCCs) dis-
rupts this feedback regulation, leading to uncontrolled
SMO signaling. Activating mutations of SMO in BCCs, on
the other hand, are resistant to PTCH1-mediated inhibi-
tion, leading to an outcome similar to PTCH1 inactivation
[3-6]. More recently, abnormal activation of the sonic
hedgehog pathway, through over-expression of sonic
hedgehog, has been implicated in the development of
subsets of medulloblastomas, small cell lung cancer and
gastrointestinal tract (GI) cancers [7-10].
Development of prostate requires hedgehog signaling.
Although the initial formation of prostate buds does not
require sonic hedgehog signaling (shh), shh is critical for
maintaining appropriate prostate growth, proliferation
and tissue polarity [11-14]. In the adult prostate, however,
the activity of the hedgehog pathway is quite low. It
remains to be tested whether this hedgehog pathway is
activated during development of prostate cancer, the sec-
ond most prevalent cause of cancer death in American
men. Activation of the hedgehog pathway is often indi-
cated by elevated levels of PTCH1 and HIP. In addition to
PTCH1 mutation, SMO activation and hedgehog over-
expression, loss of Su(Fu) can result in activation of the
hedgehog pathway. In the human, the Su(Fu) gene is
localized at chromosome 10q24, a region with LOH in
several types of cancer including prostate cancer, lung can-
cer, breast cancer and medulloblastomas [15,16]. As a
negative regulator of the hedgehog pathway, Su(Fu)
inhibits the function of Gli molecules, leading to inactiva-
tion of this pathway [17-19]. Su(Fu) is also reported to
affect beta-catenin function [20]. In addition, over-expres-
sion of sonic hedgehog is shown to be involved in the
development of GI cancers [9,10]. Here we report our
findings that activation of the hedgehog pathway occurs
frequently in advanced prostate cancers, possibly through
loss of Su(Fu) protein or over-expression of sonic
hedgehog.
Results
Elevated expression of hedgehog target genes in prostate 
cancer specimens
As an important regulator of tissue polarity, active hedge-
hog signaling is required for ductual morphogenesis and
proliferation during prostate development [11-14]. The
adult prostate, on the other hand, does not contain active
hedgehog signaling. Because hedgehog signaling is an
important regulator for epithelial-mesenchymal interac-
tion, an event critical during prostate cancer development,
we examined whether the hedgehog-signaling pathway is
activated in prostate cancer.
Activation of hedgehog signaling causes elevated expres-
sion of target genes PTCH1 and HIP. Thus, increased pro-
tein expression of PTCH1 and HIP indicates activation of
the hedgehog pathway. Using PTCH1 antibodies [10], we
examined 59 prostate cancer samples for hedgehog sign-
aling activation (see Table 1, Additional file 1 for details).
We first tested the specificity of the PTCH1 antibodies in
MEF cells. Ptch1 null MEF cells have no active Ptch1 gene,
thus should not have positive staining with PTCH1 anti-
bodies. Indeed, no staining was seen in Ptch1 null MEF
cells (Fig. 1A). After transfection of PTCH1  expressing
plasmid, transfected cells showed positive staining (Fig.
1A), indicating that the PTCH1 antibodies are specific to
PTCH1. Furthermore, PTCH1 immunohistostining was
abolished after addition of the specific peptide, from
which the antibodies were raised (Fig. 1B,1c). We found
that percentage of PTCH1 positive staining tumors
increased in high grade tumors (Table 1, Additional file
1). In prostate cancers with Gleason scores 3–6, 4 out of
18 specimens were positive for PTCH1 (22%), whereas 16
out of 22 undifferentiated carcinomas (Gleason Scores of
8–10) expressed PTCH1 (73%, see Table 1, Additional file
1), suggesting that the hedgehog pathway is frequently
activated in advanced prostate cancer. To confirm this
data, we found that all four available metastatic prostate
cancer specimens were all positive for PTCH1 staining.
To further confirm our data, we detected HIP protein
expression, another marker of the hedgehog signaling
activation. After transfection of HIP expressing plasmid
into 293 cells, HIP antibodies recognize a single band
around 75 KD (Fig. 3A), and an endogenous HIP protein
with a similar size was also detected in two cancer tissues,
in which hedgehog signaling is known to be activated
(Fig. 3B and data not shown here). In contrast, the
matched normal tissue did not express detectable HIP.
Thus, HIP expression appears to be a good marker for
hedgehog signaling activation. Immunohistostaining
with HIP antibodies in prostate cancer specimens revealed
a similar pattern to prostate specific antigen (PSA) and
PTCH1 (Fig. 3C and Table 1, Additional file 1), further
confirming that hedgehog pathway is activated inMolecular Cancer 2004, 3:29 http://www.molecular-cancer.com/content/3/1/29
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advanced prostate cancers. Thus the hedgehog pathway
appears to be frequently activated in advanced or meta-
static prostate cancers.
Altered expression of Su(Fu) and Shh in prostate cancer 
specimens
There are several mechanisms by which the hedgehog
pathway in these prostate tumors can be activated, includ-
ing loss of Su(Fu) or over-expression of hedgehog [6-10].
The Su(Fu) gene is localized at 10q24, a region with a fre-
quent LOH in prostate cancer [15,16,18]. Mutations of
Su(Fu) have been reported in other human cancers [6]. To
test whether loss of Su(Fu) function is responsible for
hedgehog signaling activation, we examined expression of
Su(Fu) protein in these prostate cancer specimens. The
antibodies of Su(Fu) recognize a single band at 52-kD in
Western blotting analyses (Fig. 4A), which was reduced
following treatment with Su(Fu) SiRNA (Fig. 4B), indicat-
ing the specificity of the antibodies. Furthermore, addi-
tion of the peptide, from which the antibodies were
raised, prevented the antibody binding, further confirm-
ing the specificity of our Su(Fu) antibodies (data not
shown). Of the 16 PTCH1 positive prostate cancer speci-
mens with Gleason scores 8–10, 9 have no detectable
Su(Fu) protein (Fig. 4C,4D,4E and Table 1, Additional file
1). In total, 11 of 27 PTCH1 positive prostate cancer spec-
imens have no detectable Su(Fu) protein. Prostate cancers
with low Gleason scores, however, frequently have
Detection of PTCH1 expression in prostate cancers Figure 1
Detection of PTCH1 expression in prostate cancers. Protein expression of PTCH1 was detected by immunostaining. 
PTCH1 antibodies (Santa Cruz Biotechnology Cat# 9149) were tested in Ptch1-/- null MEF cells (A). While Ptch1-/- null MEF cells 
had no positive fluorescent staining with PTCH1 antibodies, transfection of PTCH1 expressing plasmid lead to positive staining 
(green, indicated by an arrow, 400×). Immunohistochemistry of prostate cancer specimens with PTCH1 gave negative (B-a, 
200×) or positive (Red in B-b, 200×) signals. When PTCH1 antibodies were pre-incubated with the very peptide for raising 
the antibodies, no positive signals could be observed (B-c).
Ptch1 null MEF cells 
transfected with PTCH1 Ptch1 null MEF cells
DAPI
PTCH1
1A
1B
a. PTCH1 antibodies b. PTCH1 antibodies c. PTCH1 antibodies + peptideMolecular Cancer 2004, 3:29 http://www.molecular-cancer.com/content/3/1/29
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detectable Su(Fu) protein (see Table 1, Additional file 1),
suggesting that loss of Su(Fu) protein may be associated
with prostate cancer progression.
To confirm the immunohistochemistry data, we per-
formed immunoblotting analyses using several dissected
TURP (Transurethral resection of the prostate) specimens
in which tumor portion can be as high as 70% of the tis-
sue mass. Prostatectomy specimens (most of our tumors),
however, often contain a small percentage (5–10%) of
tumor tissue and are therefore not suitable for Western
blotting or real-time PCR analyses. As shown in Fig. 5A,
Detection of HIP in human cancer specimens Figure 3
Detection of HIP in human cancer specimens. By Western blotting, HIP antibodies (R&D systems Cat# AF1568) recog-
nized one band between 75 and100 KD (A). Expression of endogenous HIP was detected in two GI cancer tissues, which were 
known to contain activated hedgehog signaling (data not shown here), but not in the matched normal tissue (B). Immunohisto-
staining of HIP I prostate cancer showed a similar pattern to PSA (C, 200×)
HIP
PSA
250 KD
150 KD
100 KD
75 KD
50 KD
37 KD
35 KD
3A
3B
HIP
3C
Tumor 1
Tumor 2
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two tumors (PC48 and PC51) had no detectable Su(Fu)
protein, which are consistent with our immunohistostain-
ing, suggesting loss of Su(Fu) may be responsible for
hedgehog pathway activation in these tumors. The
matched normal tissues, however, retained expression of
Su(Fu), indicating that alteration of Su(Fu) is a somatic
event. Sequence analyses of these two tumors revealed
genetic mutations in Su(Fu), which are predicted to create
STOP codons in the coding sequence (Fig. 5B and Table 1,
Additional file 1). In PC48, a homozygous deletion of
A1315 was detected, which results in a STOP codon at
+1318 bp (Fig. 5B). In PC51, we detected two types of
mutations, one with a deletion of C255, which results in
a STOP codon at +294 bp whereas another with a deletion
of C198, create a STOP codon (Picture not shown here,
see Table 1, Additional file 1). These mutations were con-
firmed with 6 independent clones from two separate
experiments, which exclude the possibility of PCR errors.
No mutations were detected from the matched benign tis-
sues, indicating the somatic nature of the mutations. Real-
time PCR analyses indicated that target genes of the
hedgehog pathway, PTCH1 and Gli1, were all elevated in
these tumors (Fig. 5C), confirming activation of the
hedgehog pathway in these tumors. Thus, Su(Fu) inactiva-
tion appears to contribute to activation of hedgehog sign-
aling in these prostate tumors.
Detection of Su(Fu) in prostate cancer specimens Figure 4
Detection of Su(Fu) in prostate cancer specimens. Su(Fu) antibodies (Santa Cruz Biotechnology Cat# 10933) recog-
nized only one single band (54-Kd) in D283 cells (A). Following treatment of a specific SiRNA of Su(Fu), the endogenous Su(Fu) 
band was greatly reduced (B). Immunohistostaining with Su(Fu) antibodies in prostate cancer specimens revealed positive (C, 
in red, 200×), negative (D, 200×) or weak staining (E, red, 200×).
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For tumors with high level of PTCH1 expression, but no
changes in Su(Fu) protein expression, we examined
expression of sonic hedgehog. It is reported that expres-
sion of hedgehog may be responsible for hedgehog sign-
aling activation in lung cancer and GI cancers.
Immunohistostaining with sonic hedgehog antibodies
indicate that sonic hedgehog is highly expressed in 24 of
27 advanced prostate tumors with elevated expression of
PTCH1 and HIP (see Fig. 2 and Table 1, Additional file 1).
Thus, activation of the hedgehog pathway, as indicated by
elevated PTCH1 and HIP expression, is associated with
loss of Su(Fu) expression or elevated hedgehog
expression.
The role for activated hedgehog signaling for cellular 
functions of prostate cancer
To demonstrate the role of hedgehog pathway in prostate
cancer, we screen five available cell lines for the expression
of Gli1, PTCH1 and HIP. TSU, LNCap, Du145 and PC3
are prostate cancer cell lines whereas RWPE-1 is a prostate
epithelial cell line. We found that the hedgehog target
genes were significantly elevated in all cancer cell lines
(Fig. 6A). Thus, we predicted that inhibition of the hedge-
hog pathway by smoothened antagonist, cyclopamine,
would suppress cell proliferation and cell invasiveness.
Following treatment with 5 µM cycloapmine in PC3 cells,
expression of hedgehog target genes were dramatically
inhibited (data not shown here), which was accompanied
Inactivation of Su(Fu) in prostate cancer Figure 5
Inactivation of Su(Fu) in prostate cancer. Two TURP (Transurethral resection of the prostate) tumors with loss of 
Su(Fu) expression were confirmed by Western blotting (A). One mutation of Su(Fu) found in prostate cancer PC48 is shown 
in B, which is predicted to create a STOP codon in the Su(Fu) coding sequence +1318. The levels of Gli1 and PTCH1 tran-
scripts in prostate tissues were detected by real-time PCR (see methods for details) (C). Tumor tissues had higher levels of the 
target gene transcripts.
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with a significant reduction of BrdU positive cells (see Fig.
6B for details). This effect is specific because addition of
tomotidine, a non specific compound with a similar struc-
ture to cycloapmine, had no effects on either target gene
expression or DNA synthesis (indicated by BrdU labeling
in Fig. 6B and 6C). The prostate epithelial RWPE-1 cells
which have no activated hedgehog signaling, on the other
hand, were not sensitive to cyclopamine (data not shown
here), indicating that cyclopamine specifically affects cells
with elevated hedgehog signaling. LN-CAP, Du145 and
TSU cells, like PC3 cells were also sensitive to
cyclopamine treatment (Fig. 6C).
Prostate cancer progression is accompanied by increased
cell invasiveness. Because the hedgehog signaling activa-
tion occurs frequently in advanced prostate cancer, we
examined if inhibition of the hedgehog signaling can
reduce cell invasiveness. Using BD Bio-coat cell invasion
chambers, we found that treatment of cyclopamine in
PC3 cells reduced the percentage of invasive cells by 70%
(Fig. 7A). Similar data were also observed in Du145, LN-
CAP and TSU cells (Fig. 7B). Under the same condition,
RWPE-1 cells were not very invasive. Thus, hedgehog sig-
naling activation regulates both cell proliferation as well
as cell invasiveness of prostate cancer cells.
It has been shown that cyclopamine induced apoptosis in
cancer cells with activated hedgehog signaling [21]. We
have shown that Gli1 down-regulation is necessary for
cyclopamine-mediated apoptosis in basal cell carcinoma
cells [21]. To test the significant role of Gli1, the down-
stream effector and the target gene of the hedgehog path-
way, in cyclopamine-mediated apoptosis, we first trans-
fected Gli1 expressing plasmid in to PC3 cells, and then
treated the cells with 5 µM cyclopamine for 36 h. Since
Gli1 is expressed under the control of the CMV promoter,
we predicted that ectopic Gli1-expressing cells should be
resistant to apoptosis, which is detected by TUNEL stain-
ing. As shown in Fig. 8, we found that all Gli1 positive
cells (n = 500) were TUNEL negative, supporting our
hypothesis that down-regulation of Gli1 may be an
important mechanism by which cyclopamine mediates
apoptosis in prostate cancer cells with activated hedgehog
signaling.
Co-expression of PTCH1, PSA and Shh in prostate cancer specimens Figure 2
Co-expression of PTCH1, PSA and Shh in prostate cancer specimens. Immunohistochemistry of prostate cancer 
specimens with PSA was used to confirm the cancer region. Positive staining was in red. Positive staining patterns of PTCH1 
and Shh antibodies (Santa Cruz Biotechnology Cat# 9024) were similar to that of PSA staining. PC23 (A-C) was from tumors 
with Gleason score 7 (200×). PC38 (D-F) was a tumor from Gleason score 10 (400×) (see Table 1, Additional file 1 for 
details).
2A PC23-PSA 2C PC23-Shh 2B PC23-PTCH1
2D PC38-PSA 2E PC38-PTCH1 2F-PC38-ShhMolecular Cancer 2004, 3:29 http://www.molecular-cancer.com/content/3/1/29
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All these data indicate that the hedgehog pathway is acti-
vated in advanced prostate cancers, as indicated by high
expression of PTCH1 and HIP. Our results also indicate
that hedgehog signaling is required for cell proliferation
and cell invasion of prostate cancer cells. Thus, targeted
inhibition of the hedgehog pathway may be effective in
future prostate cancer therapeutics.
Discussion
Hedgehog signaling pathway regulates cell proliferation,
tissue polarity and cell differentiation during normal
development. Abnormal signaling of this pathway has
been reported in a variety of human cancers, including
basal cell carcinomas, medulloblastomas, small cell lung
cancer and GI cancers [3,4,6-10,22,23]. Our findings in
this report indicate a role of the sonic hedgehog pathway
in prostate cancer. We detected a high expression of
hedgehog target genes, PTCH1 and HIP, in advanced or
metastatic prostate cancers. In contrast, only 22% of pros-
tate tumors with Gleason scores 3–6 have elevated expres-
sion of PTCH1 and HIP. While our manuscript is being
reviewed, three independent groups have recently
reported similar results [24-26]. Thus, the hedgehog sign-
aling pathway is frequently activated in advanced or met-
astatic prostate cancers.
Alterations of genes in the hedgehog pathway in prostate 
cancer
In our studies, we found that some prostate tumors had
no detectable Su(Fu) protein expression while others
Cellular functions of the hedgehog pathway in prostate cancer cells Figure 6
Cellular functions of the hedgehog pathway in prostate cancer cells. Expression of hedgehog target genes, PTCH1 
and Gli1, were detected by real-time PCR (A). DNA synthesis was detected by BrdU labeling (B). Over 1000 cells were 
counted under fluorescent microscope for the percentage of BrdU positive cells, and the experiment was repeated twice (C).
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contained high levels of Shh protein expression. We fur-
ther identified inactivated mutations of Su(Fu)  in two
prostate cancers. In addition to inactivated mutations in
the coding region, Su(Fu) may be inactivated through
promoter methylation. The heterogeneous nature of pros-
tate cancer makes it difficult to screen prostate cancer
specimens for Su(Fu) mutations since the tumor content
is often less than 5% of the specimens. Future improve-
Effects of cyclopamine on cell invasiveness of prostate cancer cells Figure 7
Effects of cyclopamine on cell invasiveness of prostate cancer cells. Cell invasion assay of prostate cancer cells was 
performed using BD Bio-coat cell invasion chambers (A). The rate of cell invasion was calculated by dividing cell numbers pen-
etrated the matrigels by the number of cell in the control chambers (without matrigels) (B).
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ment can be achieved using microdissection techniques
for collecting pure population of tumor cells in gene
mutation analysis.
Since all available prostate cancer cell lines express Su(Fu)
at a high level, the role of Su(Fu) on cellular functions of
prostate cancer cannot be investigated in these cells. It
appears that over-expression of sonic hedgehog may be
responsible for hedgehog signaling activation in these cell
lines [our unpublished data and [24-26]]. After screening
over 30 human cancer cell lines, we identified non-pros-
tate cancer cell line with elevated hedgehog target genes
and no detectable Su(Fu) expression (data not shown
here). The growth suppression effects of Su(Fu) was dem-
onstrated in this cell line, in which Su(Fu) expression
down-regulated hedgehog target genes, inhibited DNA
synthesis and cell growth (data not shown here). Thus,
inactivation of Su(Fu) can contribute to active hedgehog
signaling in prostate cancer.
Su(Fu) is reported to affect β-catenin signaling [27,28].
We analyzed expression of β-catenin and E-cadherin in
our prostate cancer array and detected cytoplasmic distri-
bution of E-cadherin and β-catenin only in PC51 (data
not shown), indicating that Su(Fu) may be able to affect
both the wnt pathway and the hedgehog pathway in pros-
tate cancer.
In addition to Su(Fu) inactivation, over-expression of Shh
is another mechanism by which the hedgehog pathway is
activated in cancer [7-10]. We noticed that sonic
hedgehog expression varies from tumor to tumor, which
may be resulted from the heterogeneity of prostate cancer.
Our immunohistostaining also revealed that three tumors
(PC14, PC20 and PC36) expressed PTCH1 and HIP at
high levels, but had no alterations of Shh and Su(Fu). This
could be due to elevated expression of indian hedgehog,
or even alterations of other components of the pathway
(such as Rab23 or Fused).
Cyclopamine induces apoptosis in prostate cancer cells Figure 8
Cyclopamine induces apoptosis in prostate cancer cells. Cyclopamine-mediated apoptosis in prostate cancer cells was 
analyzed by TUNEL assay. TUNEL positive cells were indicated by arrowheads. Cells with expression of Gli1 under the CMV 
promoter (indicated by the arrows) did not undergo apoptosis (n = 500).
TUNEL ASSAYMolecular Cancer 2004, 3:29 http://www.molecular-cancer.com/content/3/1/29
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Once hedgehog pathway is activated, the target gene
expression will be up-regulated. Thus, analysis of target
gene expression using immunohistochemistry will be an
effective way to detect hedgehog pathway activation in
prostate cancer. Currently, PTCH1, Gli1 and HIP are good
markers for the hedgehog pathway.
Perspectives on prostate cancer therapy
Our findings not only provide novel basic understanding
of prostate cancer, but also allow us to design new ways to
treat prostate cancer. With a specific SMO antagonist,
cyclopamine, it will be possible in the future to treat pros-
tate cancers, which have over-expressed sonic hedgehog.
However, as a downstream molecule, tumors with Su(Fu)
inactivation may not respond to cyclopamine treatment.
Therefore, additional small molecule inhibitors appear to
be necessary to treat Su(Fu) inactivated prostate cancer.
One possibility is to use Gli1 SiRNA since we have indi-
cated that down-regulation of Gli1 may be an important
mechanism by which inhibition of the hedgehog pathway
by cyclopamine induces apoptosis (Fig. 8). Sanchez et al
also indicated that Gli1 SiRNA down-regulated DNA syn-
thesis in prostate cancer cells [24].
Conclusion
Taken together, our findings suggest that activation of the
hedgehog pathway involves prostate cancer progression.
There might be several mechanisms by which the hedge-
hog pathway is activated in advanced prostate cancers,
including loss of Su(Fu) protein expression, over-expres-
sion of sonic hedgehog or other alterations. We demon-
strate that activation of the hedgehog pathway is
associated with DNA synthesis and cell invasiveness in
prostate cancer cells. Inhibition of the hedgehog pathway,
on the other hand, causes apoptosis possibly through
down-regulation of Gli1. Our studies predict that targeted
inhibition of the hedgehog pathway may be an effective
way to prevent prostate cancer progression.
Materials and methods
Tissue Microarray of Prostate Cancer
A total of 55 paraffin-embedded tissue blocks from
patients with prostate cancer were obtained from UTMB
Surgical pathology with approval from the Institutional
Review Board (IRB). Pathological reports, H#E staining of
each specimen were reviewed to determine the nature of
the disease and the Gleason scores. Of 55 specimens, 18
were from tumors with Gleason scores 3–6, 15 with
Gleason score 7 and 22 with Gleason scores 8–10. The
tumor area was first identified before tissue microarray
(1.5 mm in diameter for specimens) was assembled with
Beecher's Tissue arrayer-I®  according to manufacturer's
instruction http://www.beecherinstruments.com.
Immunohistochemistry and Western blotting
A standard avidin-biotin immunostaining technique was
performed using a kit from Vector laboratories using spe-
cific antibodies to Su(Fu) (Santa Cruz Biotechnology Cat#
10933), PTCH1 (Santa Cruz Biotechnology Cat# 6149),
HIP (R&D systems Cat# AF1568) and Shh (Santa Cruz
Biotechnology Cat# 9024) and PSA (Vector laboratories).
Positive staining was in red or brown. The specificity of
antibodies was tested using the very peptide used for rais-
ing the antibodies, which abolished the specific staining.
Hematoxylin was used for counterstaining (in blue).
Protein was analyzed by Western analysis with appropri-
ate antibodies [Su(Fu) antibodies were from Santa Cruz,
beta-actin antibody was purchased from Sigma). The sig-
nals were visualized with the enhanced chemilumines-
cence detection system (Amersham).
Cell lines and Cell invasion assay
Cell lines (RWPE-1, Du145, PC3, LN-CAP were purchase
from ATCC and cultured according to the suggested
conditions. TSU was kindly provided by Dr. Allen Gao.
Cell invasion assay was performed with BD Bio-coat cell
invasion chambers according to manufacturer's instruc-
tion (BD Bioscience, Inc., Franklin Lakes, NJ), with tripli-
cates for each sample and the experiment was repeated
three times with the similar results. Cell were treated with
5 µM cyclopamine (or tomatidine) before (for 12 h) and
during cell invasion assay (for 24 h). The rate of cell inva-
sion was calculated by dividing cell numbers penetrated
the matrigels by the number of cell in the control cham-
bers (without matrigels).
RT-PCR and sequencing analysis
Total RNA was isolated using Trizol® reagent (Invitrogen),
and RT-PCR was performed using Promega's RT-PCR sys-
tem according to the manufacturer's protocol. Two pairs
of Su(Fu) primers were used (the first set with the forward
primer 5'-cctacgcaccccgatggcg-3" and the reverse primer
5'-agccaaaaccactacctcca-3'; the second set with the forward
primer 5'-tccaggttaccgctatcgtc-3' ad the reverse primer 5'-
tagtgtagcggactgtcg-3'). PCR products were first purified
using Qiagen's Gel Extraction Kit. Due to existence of pos-
sible Su(Fu) splicing isoforms in humans, Su(Fu) genetic
mutations were screened after the PCR products were
cloned into TOPO® TA cloning vectors (Invitrogen). Sev-
eral independent clones (from three experiments) of each
PCR product were selected for sequencing analysis in
UTMB sequencing facility. All mutations were confirmed
by at least six independent clones.
Real-time PCR We used Applied Biosystems' assays-by-
demand 20× assay mix of primers and TaqMan probes
(FAM™ dye-labeled) for the target genes (human Gli and
PTCH1, the sequences have been patented by Applied
Biosystems, Foster City, CA) and pre-developed 18S rRNAMolecular Cancer 2004, 3:29 http://www.molecular-cancer.com/content/3/1/29
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(VIC™-dye labled probe) TaqMan®  assay reagent (P/N
4319413E) for an internal control. The primers are
designed to span exon-exon junctions so as not to detect
genomic DNA and the primers and probe sequences were
searched against the Celera database to confirm specifi-
city. To obtain the relative quantitation of gene expres-
sion, a validation experiment was performed to test the
efficiency of the target amplification and the efficiency of
the reference amplification. All absolute values of the
slope of log input amount vs. ∆CT were <0.1. Separate
tubes (singleplex) one-step RT-PCR was performed with
20 ng RNA for both target genes and endogenous control.
The reagent we used was TaqMan one-step RT-PCR master
mix reagent kit (P/N 4309169). The cycling parameters
for one-step RT-PCR was: reverse transcription 48°C for
30 min, AmpliTaq activation 95°C for 10 min, denatura-
tion 95°C for 15 sec and annealing/extension 60°C for 1
min (repeat 40 times) on ABI7000. Triplicate CT values
were analyzed in Microsoft Excel using the comparative
CT(∆∆CT) method as described by the manufac-
turer(Applied Biosystems, Foster City, CA). The amount
of target (2-∆∆CT) was obtained by normalization to an
endogenous reference (18sRNA) and relative to a
calibrator.
BrdU labeling and TUNEL assay
BrdU labeling was performed using an in situ cell prolifer-
ation kit (Roche Molecular Biochemicals) [22]. Cells were
treated with 5µM cyclopamine (or tomatidine) for 12 h
before BrdU labeling (1 h at 37°C). The percentage of
BrdU positive cells was obtained by counting over 1000
cells under microscope, and the experiment was repeated
twice with similar results. TUNEL assay was performed
using an in situ cell death kit (Roche Molecular Biochem-
icals) [21,29]. Cells were treated with 5 µM cyclopamine
(or tomatidine) for 36 h before TUNEL assay).
List of abbreviations
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SMO – smoothened, BCC – basal cell carcinoma.
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